Vicasinabin
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 21, 2020 (NCT04265261)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cannabinoid CB2 receptorAGONIST
CNR2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
Cn1nnnc1Cn1nnc2c(N3CC[C@H](O)C3)nc(C(C)(C)C)nc21- Mol. weight
- 358.41 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314566 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04265261 | Phase 2 | Feb 21, 2020 | Roche |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 1 | 1 | 1 | 2020 |
1 organizations
Page 1 / 1